Navigation Links
AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe

MINNEAPOLIS, Feb. 8 /PRNewswire/ -- AGA Medical today issued the following response to a press release distributed on February 7, 2008 regarding a purported victory Occlutech GmbH had achieved in the AIPPI in AGA's patent dispute with Occlutech. The release suggested that a proceeding of some sort was conducted before the AIPPI and that organization agreed with the Occlutech position. That suggestion is false and misleading. AGA has not been involved in any proceedings with Occlutech in which AIPPI has been involved. AIPPI has not contacted AGA for its comments on any matter.

According to its charter, AIPPI is characterized as a trade and professional association and not an adjudicatory body. AIPPI does not seem to engage in any arbitration work. AIPPI is not the "European International Association for the Protection of Intellectual Property" as Occlutech claims, but is simply the International Association for the Protection of Intellectual Property, having no connection with any European governmental entity.

The facts are as follows: after being found to be an infringer of AGA's patent in Germany, Occlutech has made two attempts to stay enforcement in Germany, both of which were unsuccessful. They made an unsuccessful attempt to obtain a ruling of non-infringement/invalidity in Italy that did not succeed. In addition, Occlutech has been found guilty of violating the Court order on infringement in Germany and was fined by the court. The injunction of the German court remains in place.

Additionally, AGA Medical is exploring remedies under German law that might be available to prevent such misrepresentations from continuing.

ABOUT AGA MEDICAL: AGA Medical Corporation, based in Plymouth, Minnesota (just outside Minneapolis) is the leader in developing interventional devices to treat structural heart defects. As a result of the many contributions and creative genius of Dr. Kurt Amplatz, the Company has developed and commercializes a series of devices that have revolutionized the treatment of the most common congenital "holes in the heart" such as atrial septal and patent foramen ovale defects. The company is expanding into new areas such as the minimally invasive repair of vascular abnormalities. Over 790 articles have been published in peer reviewed medical publications that support the benefits of AGA Medical devices including improved patient outcomes, reduced length of stay and accelerated recovery times for the patient, AGA Medical devices have received regulatory approval and are marketed in over 100 countries with over 278,000 devices shipped to date. For more information visit


Devin Nagy

Brunswick Group LLC


SOURCE AGA Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
2. BioMS Medical to present at BIO CEO & Investor Conference
3. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
4. Linc Facility Services Acquires Morse Medical
5. Perrigo Company to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program
8. Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
9. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
10. Medical University of South Carolina Opens State-of-the-Art Facility
11. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon ... awards honoring scientists who have made outstanding contributions to analytical chemistry ... Pittcon 2018, the world’s leading conference and exposition for laboratory science, which will ...
Breaking Biology Technology:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
Breaking Biology News(10 mins):